Tim Shaw

3.3k total citations · 2 hit papers
16 papers, 2.5k citations indexed

About

Tim Shaw is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Tim Shaw has authored 16 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Rheumatology, 9 papers in Hematology and 4 papers in Genetics. Recurrent topics in Tim Shaw's work include Rheumatoid Arthritis Research and Therapies (14 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Tim Shaw is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (14 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Tim Shaw collaborates with scholars based in United States, United Kingdom and Australia. Tim Shaw's co-authors include Jonathan Edwards, D. Close, L Szczepański, Jacek Szechiński, Paul Emery, Randall M. Stevens, Anna Filipowicz‐Sosnowska, Stanley Cohen, Charles Peterfy and Sunil Agarwal and has published in prestigious journals such as New England Journal of Medicine, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

Tim Shaw

15 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

2004 1.9k citations Jonathan Edwards, L Szczepański et al. New England Journal of Medicine profile →
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

2023 124 citations Gerd R Burmester, Stanley Cohen et al. RMD Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tim Shaw United States	9	1.3k	902	640	576	463	16	2.5k
D. Close United States	15	1.5k 1.1×	1.2k 1.3×	807 1.3×	548 1.0×	442 1.0×	26	3.0k
E. Hessey United Kingdom	6	1.7k 1.3×	732 0.8×	615 1.0×	710 1.2×	650 1.4×	8	2.4k
Matthew Cravets United States	5	1.1k 0.8×	616 0.7×	390 0.6×	470 0.8×	467 1.0×	6	2.0k
Anna Filipowicz‐Sosnowska Poland	8	1.8k 1.3×	1.1k 1.2×	798 1.2×	728 1.3×	588 1.3×	36	3.4k
Carla A. Wijbrandts Netherlands	30	1.7k 1.3×	1.1k 1.2×	619 1.0×	369 0.6×	461 1.0×	47	2.9k
Joy Schechtman United States	11	1.1k 0.8×	533 0.6×	405 0.6×	360 0.6×	421 0.9×	17	1.7k
John Bowes United Kingdom	33	1.3k 1.0×	1.3k 1.4×	327 0.5×	344 0.6×	407 0.9×	86	2.8k
Satoshi Kubo Japan	32	1.6k 1.2×	1.2k 1.3×	252 0.4×	368 0.6×	454 1.0×	157	3.0k
Saeed Fatenejad United States	23	2.9k 2.2×	1.2k 1.3×	430 0.7×	479 0.8×	1.2k 2.6×	37	3.8k
Arthur F. Kavanaugh United States	17	2.8k 2.1×	1.0k 1.1×	539 0.8×	537 0.9×	1.2k 2.7×	27	3.7k

Countries citing papers authored by Tim Shaw

Since Specialization

Citations

This map shows the geographic impact of Tim Shaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Shaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Shaw more than expected).

Fields of papers citing papers by Tim Shaw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Shaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Shaw. The network helps show where Tim Shaw may publish in the future.

Co-authorship network of co-authors of Tim Shaw

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Shaw. A scholar is included among the top collaborators of Tim Shaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Shaw. Tim Shaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Burmester, Gerd R, Stanley Cohen, Kevin Winthrop, et al.. (2023). Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 9(1). e002735–e002735. 124 indexed citations breakdown →

Mysler, Eduardo, Yoshiya Tanaka, Arthur Kavanaugh, et al.. (2022). Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE. Lara D. Veeken. 62(5). 1804–1813. 6 indexed citations

Shaw, Tim, Gerd R Burmester, Stanley Cohen, et al.. (2022). P220 Long-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Lara D. Veeken. 61(Supplement_1). 2 indexed citations

Conaghan, Philip G., Eduardo Mysler, Yoshiya Tanaka, et al.. (2021). Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program. Drug Safety. 44(5). 515–530. 33 indexed citations

Conaghan, Philip G., Stanley Cohen, Gerd R Burmester, et al.. (2021). Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy. 9(1). 191–206. 6 indexed citations

Peterfy, Charles, Vibeke Strand, Alan Friedman, et al.. (2021). Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. Lara D. Veeken. 61(8). 3246–3256. 8 indexed citations

Hall, Stephen, Tsutomu Takeuchi, G. T. D. Thomson, et al.. (2019). THU0174 CHARACTERIZATION OF REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB OR COMPARATORS. Annals of the Rheumatic Diseases. 78. 362–362.

Peterfy, Charles, Mark C. Genovese, In‐Ho Song, et al.. (2019). THU0188 INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1 YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAM. Annals of the Rheumatic Diseases. 78. 369–370. 1 indexed citations

Adebajo, Adewale, et al.. (2015). Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opinion on Pharmacotherapy. 16(7). 1099–1108. 32 indexed citations

10.

Tak, Paul P., William F. C. Rigby, Andrea Rubbert‐Roth, et al.. (2011). Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Annals of the Rheumatic Diseases. 71(3). 351–357. 79 indexed citations

11.

Peterfy, Charles, P.J. Countryman, Annarita Gabriele, et al.. (2011). Magnetic Resonance Imaging in Rheumatoid Arthritis Clinical Trials: Emerging Patterns Based on Recent Experience. The Journal of Rheumatology. 38(9). 2023–2030. 17 indexed citations

12.

Cohen, Stanley, Edward Keystone, Mark C. Genovese, et al.. (2010). Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Annals of the Rheumatic Diseases. 69(6). 1158–1161. 62 indexed citations

13.

Attinger, Christopher E., Terry Treadwell, Michael McGovern, et al.. (2009). A Multidisciplinary Approach to Limb Preservation: The Role of V.A.C. ® Therapy. 4 indexed citations

14.

Breedveld, Ferdinand C., Sunil Agarwal, Ming Yin, et al.. (2007). Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response. The Journal of Clinical Pharmacology. 47(9). 1119–1128. 110 indexed citations

15.

Edwards, Jonathan, L Szczepański, Jacek Szechiński, et al.. (2004). Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. New England Journal of Medicine. 350(25). 2572–2581. 1950 indexed citations breakdown →

16.

Shaw, Tim, John Nixon, & K M K Bottomley. (2000). Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis. Expert Opinion on Investigational Drugs. 9(7). 1469–1478. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact